{
    "2021-11-24": [
        [
            {
                "time": "",
                "original_text": "借道18A两次冲击上市，却又退钱延遲发售！当故事无法兑现，企业如何过冬？",
                "features": {
                    "keywords": [
                        "18A",
                        "上市",
                        "退钱",
                        "延迟发售",
                        "企业生存"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "新股精要：极具竞争力的创新驱动型生物医药公司迪哲医药",
                "features": {
                    "keywords": [
                        "新股",
                        "迪哲医药",
                        "创新驱动",
                        "生物医药"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "贝达药业董事长：公司将以40%的收入用于创新，目前有30多项在研创新药",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "创新投入",
                        "在研创新药"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业周报：CDE发布《以临床价值为导向的抗肿瘤药物临床研发指导原则》",
                "features": {
                    "keywords": [
                        "医药生物",
                        "CDE",
                        "临床价值",
                        "抗肿瘤药物",
                        "研发指导原则"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业双周报",
                "features": {
                    "keywords": [
                        "医药生物",
                        "双周报"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}